Weekly Funding Opportunities

[med-Research]

Dear Colleague Letter: UKRI/BBSRC - NSF/BIO Lead Agency Opportunity in Biological informatics, Microbes and the Host Immune System, Quantum Biology, and Synthetic Cell<https://www.nsf.gov/pubs/2021/nsf21100/nsf21100.jsp?WT.mc_id=USNSF_25&WT.mc_ev=click>
Through this Dear Colleague Letter (DCL), the NSF Directorate for Biological Sciences (NSF/BIO) and the UKRI Biotechnology and Biological Sciences Research Council (BBSRC) are pleased to announce 2021/2022 topical areas associated with this lead agency opportunity. The lead agency opportunity allows for reciprocal acceptance of peer review through unsolicited mechanisms; its goal is to help reduce some of the current barriers to working internationally. Topics of interest:
Biological Informatics
Proposals are invited that address the development of novel informatics approaches and cyberinfrastructure resources to enable novel and effective use of data in biological research, addressing key challenges faced by researchers and supporting generation of new knowledge from biological data. Proposals must be aligned to BOTH NSF's Division of Biological Infrastructure programs in informatics and cyberinfrastructure AND UKRI/BBSRC's Data Driven Biology<https://www.nsf.gov/cgi-bin/goodbye?http://www.bbsrc.ac.uk/funding/grants/priorities/data-driven-biology/> Responsive Mode priority. In addition, Principal Investigators (PIs) are advised to consult the appropriate program officer to ensure that their portion of the project is compliant with the targeted program.
Microbes and the Host Immune System
Proposals are invited that take an integrated approach to answer important questions relating to the immune system and host-microbe interactions. Microbes impact their hosts in manners that result in greatly different outcomes, which can include symbiotic, mutualistic or pathogenic infection. Key to these outcomes is the response and resilience of the host innate and adaptive immune system, as well as the microbial players (bacterial, fungal, viral) and the underlying physiological context. Relevant areas of investigation include systems using genetically-similar hosts or microbes that result in different phenotypic outcomes of infection. The use of comparative cross-species approaches to develop insights that have broad relevance across biological organisms is encouraged, as is research to understand the influence of co-infection and the wider microbiome and the influence of host physiology through the life course. Proposals should aim to identify molecular mechanisms or develop systems-level understanding. Proposals that focus on industrial applications will not be accepted. Proposals that focus solely on human or mouse immune systems will not be accepted. Proposals must aim to progress knowledge of immunology in non-human animals or plants.
Quantum Biology
Proposals are invited that seek to investigate the biological molecules and biomolecular systems that give rise to quantum mechanical effects in living organisms. Studies have shown that such phenomena are important to a number of fundamental biological processes, including photosynthesis, olfaction, cellular respiration, and vision, yet the specialized features that enable such effects are not well understood. Relevant areas of investigation include the features of proteins that enable quantum effects to occur at physiological temperatures and the significance of the relatively large size of most protein complexes that exhibit quantum phenomena in contributing to the superposition of quantum states that give rise to quantum entanglement or quantum coherence. Mechanistic insight into the extended coherence times observed in biological systems is also of interest. In addition to biophysical mechanisms, proposals that aim to provide insights into the prevalence of quantum phenomena in biological systems across the tree of life and their evolutionary origins are also welcome. Proposals must aim to progress biological understanding and are expected to integrate research and methodologies from both (bio)physics and biology.
Synthetic Cell
Can we design, build and control a synthetic cell? Realizing this grand challenge will enable us to uncover the molecular and physical organization of cells that enable storage and transmittal of information, capture and transformation of energy, and adaptation and regulation of cellular systems that make life possible. Natural cells emerge from the coordinated operation of a large number of biomolecules with their environment. One goal of synthetic cell research is to decipher the basic requirements of a living cell by understanding the myriad functions that make it resilient and adaptive. To this end, proposals are expected to focus on building a synthetic cell in order to understand biology. For example, the identification of genes, metabolic pathways and cellular components and the molecular mechanism by which they exert their function can inform and accelerate the design and building of synthetic cells. Such cells might be protocells containing only the most basic cellular components that allows an understanding of the origin of life, artificial cells that contain both natural and synthetic cellular components or minimal cells that use natural molecules to build self-replicating cellular entities through 'bottom up' approaches. Proposals focused exclusively on building a synthetic cell as a biomanufacturing platform or as a therapeutic moiety will not be accepted.
2-page intention to submit due September 22, 2021. Med-RA deadline to receive draft documents: September 9.

Technology Development for Single-Molecule Protein Sequencing and Single-Cell Proteome Analysis (R21 / R01 Clinical Trial not allowed)
R21<http://This%20Funding%20Opportunity%20Announcement%20(FOA)%20solicits%20R21%20grant%20applications%20to%20catalyze%20major%20advances%20in%20single-molecule%20protein%20sequencing%20through%20technology%20development.%20The%20goal%20of%20this%20initiative%20is%20to%20achieve%20technological%20advances%20over%20the%20next%20five%20years%20that%20enable%20generation%20of%20protein%20sequencing%20data%20at%20sufficient%20scale,%20speed,%20cost%20and%20accuracy%20to%20use%20routinely%20in%20studies%20of%20genome%20biology%20and%20function,%20and%20in%20biomedical%20and%20clinical%20research%20in%20general.%20Exploration%20of%20methods%20other%20than%20those%20currently%20in%20use%20is%20highly%20encouraged.%20High-risk/high-payoff%20applications%20are%20appropriate%20to%20achieve%20the%20goals%20of%20this%20FOA.>
This Funding Opportunity Announcement (FOA) solicits R21 grant applications to catalyze major advances in single-molecule protein sequencing through technology development. The goal of this initiative is to achieve technological advances over the next five years that enable generation of protein sequencing data at sufficient scale, speed, cost and accuracy to use routinely in studies of genome biology and function, and in biomedical and clinical research in general. Exploration of methods other than those currently in use is highly encouraged. High-risk/high-payoff applications are appropriate to achieve the goals of this FOA.
R01<https://grants.nih.gov/grants/guide/rfa-files/RFA-HG-21-001.html>
This Funding Opportunity Announcement (FOA) solicits grant applications to catalyze major advances in single-molecule protein sequencing and single cell proteome analysis through technology development. The goal of this initiative is to achieve technological advances over the next five years that enable generation of protein sequencing data at sufficient scale, speed, cost and accuracy to use routinely in studies of genome biology and function, and in biomedical and clinical research in general.
Due October 1, 2021; June 15, 2022; June 15, 2023. Med-RA deadline to receive draft documents: September 20.

Large Research Projects for Prevention of Healthcare-Associated Infections (R01)<https://grants.nih.gov/grants/guide/pa-files/PA-21-265.html>
This FOA issued by AHRQ invites grant applications for funding to conduct Large Research Projects (R01) that propose to advance the base of knowledge for detection, prevention, and reduction of Healthcare-Associated Infections (HAIs). This FOA describes the broad areas of HAI research for which funds are available to support Large Research Projects.
Standard dates apply. Expires May 27, 2025. Med-RA deadline to receive draft documents for October 5, 2021 standard date: September 22.

Pediatric Immune System – Ontogeny and Development (INTEND) (R01 Clinical Trial Not Allowed) <https://grants.nih.gov/grants/guide/pa-files/PAR-21-248.html>
The purpose of this Funding Opportunity Announcement (FOA) is to correlate immune system development patterns between two or more age groups – neonates, infants, and children and adolescents and further understand the impact of infectious diseases, microbiome and environmental factors on the ontogeny and development of the pediatric immune system, from birth, transitioning into adolescence and adulthood with the focus of impact during pregnancy and post-natal period.
Due October 5, 2021; February 5, 2022; October 5, 2022; February 5, 2023; October 5, 2023; February 5, 2024. Med-RA deadline to receive draft documents for October 5, 2021 due date: September 22.

Metabolic Dysregulation and Cancer Risk Program, Research Grants: a Transdisciplinary Approach to Obesity-Associated Research (U01 Clinical Trial Optional)<https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-21-021.html>
The National Cancer Institute (NCI) invites research grant applications for transdisciplinary studies that will enhance our knowledge of the dynamics and underlying mechanisms that link obesity, metabolic dysregulation and increased cancer risk as part of the Metabolic Dysregulation and Cancer Risk Program. Through this Funding Opportunity Announcement (FOA), the Metabolic Dysregulation and Cancer Risk Program will focus on metabolic dysregulation as the key process linking obesity with cancer risk. For the purpose of this FOA, metabolic dysregulation is defined as alterations in glucose utilization and storage, insulin sensitivity, and/or lipid metabolism. Applications should specifically seek to advance our understanding of how metabolic dysregulation in individuals affects cancer risk and identify mechanisms that will enhance (i) cancer risk prediction, (ii) screening for high-risk individuals in clinical settings, and (iii) identification of potential targets for preventive and therapeutic interventions.
Due October 6, 2021. Med-RA deadline to receive draft documents: September 23.

Cancer Target Discovery and Development (CTD2) (U01 Clinical Trial Not Allowed)<https://grants.nih.gov/grants/guide/pa-files/PAR-21-274.html>
Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) will support the program “Cancer Target Discovery and Development” (CTD2, pronounced cee-tee-dee-squared). CTD2 is focused on efforts that advance cancer research by bridging the knowledge gap between the large volumes of comprehensive molecular characterizations of many cancer types and studies of the underlying etiology of cancer development, progression, and/or metastasis.
The primary purpose of CTD2 is to advance the following areas:

  *   Improving the understanding of how mutations in cancer-associated genes affect the protein activity (e.g., gain-of-function, loss-of-function, or neomorphic function) within the cellular pathway(s) they are part of and the cellular changes that result within the context of various tumors and the microenvironment;
  *   Identifying new molecular targets with the goal to understand their wiring mechanisms and how to overcome innate and/or acquired resistance to therapies, particularly clinical resistance related to inter- and intra- tumor heterogeneity; and
  *   Developing efficient strategies to identify appropriate multiple targets and optimal combination of perturbagens (chemical or biological; immunotherapeutics being a prime example of the latter) with the potential to eliminate all cancer cells, despite their clonal heterogeneity and their surrounding microenvironment.
This FOA solicits applications for U01 cooperative agreement research projects addressing the areas outlined above. The proposed projects should use a combination of state-of-the-art high throughput informatic and experimental approaches to: characterize and validate novel cancer targets; develop precise perturbagens that can affect the proposed targets of cancer treatments and define the mechanism(s) of action; identify molecular markers that can meaningfully predict responses or resistance to anticancer therapies and develop algorithms that can be applied to predict responses to treatments and/or define more precise treatment modalities.
Due October 6, 2021; February 8, 2022; October 6, 2022. Med-RA deadline to receive draft documents for October 6, 2021 due date: September 23.

R01: BRAIN Initiative: Research on the Ethical Implications of Advancements in Neurotechnology and Brain Science<https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-21-205.html>
Guided by the goals established in BRAIN 2025: A Scientific Vision<https://braininitiative.nih.gov/pdf/BRAIN2025_508C.pdf> and reinforced by the Advisory Council to the Director Working Group on BRAIN 2.0 Neuroethics Subgroup<https://acd.od.nih.gov/working-groups/brain2.0-subgroup.html>, this Funding Opportunity Announcement (FOA) from the NIH Brain Research through Advancing Innovative Neurotechnologies® (BRAIN) Initiative is intended to support efforts addressing core ethical issues associated with research focused on the human brain and resulting from emerging technologies and advancements supported by the BRAIN Initiative. This FOA encourages research project grant applications from multi-disciplinary teams focused on key ethical issues associated with BRAIN Initiative supported research areas. Efforts supported under this FOA are intended to be both complementary and integrative with the transformative, breakthrough neuroscience discoveries supported through the BRAIN Initiative.
Due October 13, 2021; October 11, 2022; October 11, 2023. Med-RA deadline to receive draft documents for October 13, 2021 due date: September 30.

HEAL Initiative: Novel Targets for Opioid Use Disorders and Opioid Overdose (R21 / R01 Clinical Trial Not Allowed)
R21<https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-22-032.html>
R01<https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-22-031.html>
The purpose of these Funding Opportunity Announcements (FOAs) is to support research projects focusing on the identification of druggable new targets and discovery of optimizable probes for development of safe and efficacious medications to prevent and treat opioid use disorders (OUDs), opioid overdose, and opioid-polysubstance use comorbidities. These FOAs are part of the NIH Helping to End Addictions Long-term (HEAL) initiative to accelerate the development of novel medications to treat all aspects of the opioid addiction cycle, including progression to chronic use, withdrawal symptoms, craving, relapse, and overdose.
Due October 19, 2021. Med-RA deadline to receive draft documents: October 6.

Identification and Characterization of Bioactive Microbial Metabolites for Advancing Research on Microbe-Diet-Host Interactions (R01 Clinical Trial Not Allowed)<https://grants.nih.gov/grants/guide/pa-files/PAR-21-253.html>
The purpose of the Funding Opportunity Announcement is to invite applications to identify and characterize microbial metabolites that will establish causal associations between microbial metabolism and host health and disease. Data acquired through this initiative will be used to create a knowledge base of microbial metabolites and associated functions that will be provided to the research community.
Due October 20, 2021; June 22, 2022; October 20, 2022; June 22, 2023; October 19, 2023. Med-RA deadline to receive draft documents for October 20, 2021 due date: October 7.

Aging Research in Animals (ARIA): Promoting Rigorous Research on Behavioral and Social Processes (R61 / R33 Clinical Trial Not Allowed)<https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-22-015.html>
The overarching objective of this funding opportunity announcement (FOA) is to develop and strengthen animal models for behavioral and social research in the interest of furthering the mechanistic understanding of how social and physical environmental factors contribute to aging processes and the etiology and progression of age-related conditions and diseases. With the explicit two-fold goal of identifying socio-environmental sources of aging processes and advancing the integration of behavioral, social, and environmental measures into biological hallmarks of aging, this FOA invites R61/R33 phased innovation applications that propose to develop and test behavioral and social methods, tools, and measures in: (1) research on the natural history of aging in populations of wild animals to increase the understanding of the complex interplay of social and environmental factors which affect individual differences in aging trajectories and health outcomes; and (2) basic and applied research in captive animals that can improve the validity and value of animal models for basic and translational research. Funded projects will receive up to two years of R61 support for initial developmental, proof-of-concept activities, and up to three years of R33 research to support implementation. Projects may involve primary or secondary analysis of data collected in animals from well-characterized wild populations, captive populations, or both.
Due October 20, 2021. Med-RA deadline to receive draft documents: October 7.

Primary Care-Based Screening and Intervention Development for Prevention of Abuse in Older and Vulnerable Adults in the Context of Alzheimer’s Disease and Related Dementias (R61 / R33 Clinical Trial Required)<https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-22-024.html>
The purpose of this funding opportunity announcement (FOA) is to support research that can lead to the development of evidence-based primary care screening tools and behavioral interventions to prevent abuse in at-risk older and vulnerable adults with mild cognitive impairment (MCI) and Alzheimer’s disease and Alzheimer’s disease-related dementias (AD/ADRD) and their families. Specifically, this FOA invites R61/R33 applications proposing Stage I screening and behavioral intervention development and Stage III efficacy trials in primary care settings. Studies must directly address the priority research needs and gaps highlighted in the U.S. Preventive Services Task Force’s 2018 final recommendation statement on Intimate Partner Violence, Elder Abuse, and Abuse of Vulnerable Adults: Screening<https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/intimate-partner-violence-and-abuse-of-elderly-and-vulnerable-adults-screening> for the development and validation of the following:

  1.  Reliable and accurate screening instruments or assessments in primary care settings for older and vulnerable adults without recognized signs or symptoms of abuse (i.e., asymptomatic), and for their medical visit companions, at the time of diagnosis of MCI or AD/ADRD and subsequent primary care encounters; and/or
  2.  Brief and effective point-of-care psychoeducational and behavioral interventions for the prevention of all types of abuse.
Due October 20, 2021. Med-RA deadline to receive draft documents: October 7.

Computational Approaches for Validating Dimensional Constructs of Relevance to Psychopathology (R01 Clinical Trial Optional) / Computationally-Defined Behaviors in Psychiatry (R21 Clinical Trial Optional)
Computational Approaches for Validating Dimensional Constructs of Relevance to Psychopathology (R01 Clinical Trial Optional)<https://grants.nih.gov/grants/guide/pa-files/PAR-21-263.html>
This Funding Opportunity Announcement (FOA) solicits applications for research projects that will use computational approaches to test the validity of dimensional constructs in the NIMH Research Domain Criteria (RDoC) matrix<https://www.nimh.nih.gov/research-priorities/rdoc/index.shtml> (or similar constructs based on comparable criteria). Some elements of the RDoC matrix have been updated since its first release, but a thorough data-driven validation that broadly explores, compares, and validates the constructs within the matrix has not been performed. This FOA seeks research that addresses the following questions: Do the different domains of behavior segregate from each other? How much do they rely on distinct versus overlapping neural circuits? What are the relationships between domains, constructs, and subordinate sub-constructs, both in terms of their correlational structure and their underlying neural circuitry? By answering these questions, proposed research projects will test integrative models of functioning and identify dysregulation in psychopathology-related mechanisms that may cut across traditional diagnostic categories and may change over time. This FOA seeks to promote projects where the computational and the experimental components are well integrated. To ensure ecological validity of these studies, models derived from lab-based behavioral tasks will need to be tested for generalizability to behavioral data collected in a real-world setting. The ultimate goal is to advance translational research that will identify novel classification approaches and/or treatment targets, and lead to more effective and timely interventions for serious mental illnesses.
Computationally-Defined Behaviors in Psychiatry (R21 Clinical Trial Optional)<https://grants.nih.gov/grants/guide/pa-files/PAR-21-264.html>
This Funding Opportunity Announcement (FOA) solicits applications for research projects that will apply computational approaches to develop parametrically detailed behavioral assays across mental-health relevant domains of function. These projects should focus on behavior in humans and test computational models in healthy, trans-diagnostic, unselected, or community samples. NIMH is particularly interested in the study of behavioral measures, models, and parameters that have the potential for back-translation from humans to animals, especially for pre-clinical therapeutics development, and in models that have the potential to be extended to clinical populations. To maximize prospects of back-translation and to provide a neurobiological foundation for future research, studies will need to consider behavioral models and parameters that are linked to the underlying neural processes that may be involved in their computation. Finally, in order to ensure ecological validity of behavioral assays, models derived from lab-based behavioral tasks will need to be tested for generalizability to behavioral data collected in a real-world setting.
Due November 1, 2021; November 1, 2022; November 1, 2023. Med-RA deadline to receive draft documents for November 1, 2021 due date: October 19.

Elucidating the Roles of Transposable Elements in AD/ADRD and Aging (R01 Clinical Trial Not Allowed)<https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-22-021.html>
The goal of this Funding Opportunity Announcement (FOA) is to support hypothesis-driven research to gain an understanding of the dysregulation of transposable elements (TE) and their contributions to Alzheimer’s disease (AD) and Alzheimer’s disease-related dementias (ADRD) and aging. This FOA encourages applications that investigate causal effects of TE activation in disease and aging and applications that model therapeutic interventions to facilitate the transition of the field from observational discovery towards a deeper mechanistic understanding of the function and regulation of TEs.
Due November 2, 2021. Med-RA deadline to receive draft documents: October 20.

Growing Great Ideas: Research Education Course in Product Development and Entrepreneurship for Life Science Researchers (UE5 Clinical Trial Not Allowed)<https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-22-020.html>

  *   Courses for Skills Development
  *   Curriculum or Methods Development
This FOA seeks applications to develop a customized curriculum and implement education programs/short courses in biomedical entrepreneurship, innovation and biomedical product development, specifically targeting scientists working in the field of drug addiction research. The institution proposing the course must be an institution that has an established and well-recognized entrepreneurship teaching program with the demonstrated ability and passion to adapt/develop and deliver an integrated curriculum for academic life scientists.
Due November 18, 2021. Med-RA deadline to receive draft documents: November 4 (due to Veterans Day holiday).

Innate Immune Memory Impacting HIV Acquisition and/or Control (R21 Clinical Trial Not Allowed)<https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-21-041.html>
The purpose of this Funding Opportunity Announcement is to investigate innate immune cell effector functions and innate immune memory as a means to prevent HIV infection and/or establishment of disease. Exploratory research from basic molecular mechanisms, translational work, and clinical research examining innate memory are encouraged.
Due December 6, 2021. Med-RA deadline to receive draft documents: November 22 (due to Thanksgiving holiday).

Elucidating the Effects of ART on Neuronal Function in the Context of SUD and HIV (R01 – Clinical Trials Not Allowed)<https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-22-003.html>
The National Institute on Drug Abuse [NIDA] seeks research applications to identify the effects of anti-retroviral therapy (ART) used for the treatment of HIV/AIDS on neuronal and glial structure and function, particularly when occurring in a background of chronic exposure to addictive substances including opioids, cocaine and other stimulants, cannabinoids, and nicotine. The overall goal of this funding opportunity is to determine the contributions of ART in the neurological and neurocognitive deficits that are linked to HIV-Associated Neurocognitive Disorders [HAND] in people living with HIV (PLWH) and substance use disorders (SUD).
Due February 2, 2022. Med-RA deadline to receive draft documents: January 20.

Dyadic Interpersonal Processes and Biopsychosocial Outcomes (R01s)
R01 Clinical Trials Not Allowed<https://grants.nih.gov/grants/guide/pa-files/PAR-21-281.html>
This funding opportunity announcement (FOA) invites basic and/or methodological research projects that seek to illuminate or measure independent and interdependent health-related effects within dyads. For the purpose of this FOA, a dyad is a unit of two individuals whose interactions and influences on one another are nested within larger social contexts and networks. Both animal and human subjects research projects are welcome. Types of projects submitted under this FOA include but are not limited to, observational studies involving humans, or existing/synthesized datasets studies.  Researchers proposing basic science experimental studies involving human participants (i.e., experimentally manipulate independent variables) should consider the companion FOA PAR-21-280<https://grants.nih.gov/grants/guide/pa-files/PAR-21-280.html>” Dyadic Interpersonal Processes and Biopsychosocial Outcomes (R01 Basic Experimental Studies with Humans).”
Due February 5, 2022 and February 5, 2023. Med-RA deadline to receive draft documents for February 5, 2022 due date: January 25.
R01 Basic Experimental Studies with Humans<https://grants.nih.gov/grants/guide/pa-files/PAR-21-280.html>
This funding opportunity announcement (FOA) invites basic and/or methodological research projects that illuminate and/or measure independent and interdependent health-related effects within dyads across relationships and settings. For the purpose of this FOA, a dyad is a unit of two individuals whose interactions and influences on one another are nested within larger social contexts and networks. Dyads are social relationships that extend beyond the individual and have strong bidirectional influences on physical and mental health. For the purpose of this FOA, independent effects are those effects that affect each member of the dyad individually (i.e., by nature of being part of the dyad), whereas interdependent effects are those that affect one member of the dyad contingent upon the other member of the dyad (i.e., not only because the individual is part of a dyad but also because being part of the dyad has an effect on the other individual within the dyad as well).
Due March 5, 2022 and March 5, 2023. Med-RA deadline to receive draft documents for March 5, 2022 due date: February 22.

New Investigators to Promote Workforce Diversity in Genomics, Bioinformatics, or Bioengineering and Biomedical Imaging Research (R01 Clinical Trial Optional)<https://grants.nih.gov/grants/guide/rfa-files/RFA-HG-21-025.html>
This Funding Opportunity Announcement (FOA) solicits R01 grant applications that propose independent research projects that are within the scientific mission areas of the National Human Genome Research Institute (NHGRI), National Institute of Biomedical Imaging and Bioengineering (NIBIB), and All of Us Research Program (All of Us). This program is intended to support Early Stage Investigators and New Investigators<https://grants.nih.gov/policy/early-investigators/index.htm> from groups underrepresented in the health-related sciences.
Due February 22, 2022 and February 22, 2023. Med-RA deadline to receive draft documents for February 22, 2022 due date: February 9.

NIDA Animal Genomics Program (U01 – Clinical Trial Not Allowed)<https://grants.nih.gov/grants/guide/pa-files/PAR-21-244.html>
The purpose of the NIDA Animal Genetics Program is to identify genetic, genomic, and molecular (epi)genetic variants that underlie: 1. Phenotypes associated with addictive behaviors and/or vulnerability to distinct stages along the substance use disorder (SUD) trajectory (e.g. initial/acute use, escalation of use, acquisition of tolerance, dependence, uncontrolled use, abstinence and relapse or recovery); 2. Behaviors associated with SUD (e.g. impulsivity, novelty seeking, delayed discounting, and other genetically-associated phenotypes); and 3. Comorbidities that demonstrate genetic correlations with phenotypes and behaviors linked with SUD (e.g. anxiety, stress, poor maternal care, social defeat, and other paradigms). Applications may examine any type of variant, including single nucleotide variants (SNVs), indels, large and small structural variants, and all types of mobile DNA. NIDA encourages applications that take genomics, multi-omics, and/or data-based approaches that integrate multi-level ‘omics data, delineate gene networks, and/or uncover the function of known or newly discovered genetic or epigenetic variants. NIDA expects these studies to uncover novel mechanisms that contribute to SUD and facilitate the discovery of targets for intervention and guide the development of individualized therapeutics to treat these different aspects of SUD.
Due March 2, 2022; July 26, 2022; March 2, 2023; July 26, 2023; March 4, 2024. Med-RA deadline to receive draft documents for March 2, 2022 due date: February 17.

Biophtonics<https://www.nsf.gov/funding/pgm_summ.jsp?pims_id=505719>
The Biophotonics program is part of the Engineering Biology and Health cluster, which also includes: 1) the Biosensing program; 2) the Cellular and Biochemical Engineering program; 3) the Disability and Rehabilitation Engineering program; and 4) the Engineering of Biomedical Systems program.
The goal of the Biophotonics program is to explore the research frontiers in photonics principles, engineering and technology that are relevant for critical problems in fields of medicine, biology and biotechnology.  Fundamental engineering research and innovation in photonics is required to lay the foundations for new technologies beyond those that are mature and ready for application in medical diagnostics and therapies.  Advances are needed in nanophotonics, optogenetics, contrast and targeting agents, ultra-thin probes, wide field imaging, and rapid biomarker screening. Low cost and minimally invasive medical diagnostics and therapies are key motivating application goals.
Research topics in this program include:

  *   Imaging in the second near infrared window: Research that advances medical applications of biophotonics in the second near-infrared window (NIR-II: 1,000-1,700 nm) in which biological tissues are transparent up to several centimeters in depth, making this spectral window ideal for deep tissue imaging.
  *   Macromolecule markers: Innovative methods for labeling of macromolecules. Novel compositions of matter. Methods of fabrication of multicolor probes that could be used for marking and detection of specific pathological cells. Pushing the envelope of optical sensing to the limits of detection, resolution, and identification.
  *   Low coherence sensing at the nanoscale: Low coherence enhanced backscattering (LEBS). N-dimensional elastic light scattering. Angle-resolved low coherence interferometry for early cancer detection (dysplasia).
  *   Neurophotonics: Studies of photon activation of neurons at the interface of nanomaterials attached to cells. Development and application of biocompatible photonic tools such as parallel interfaces and interconnects for communicating and control of neural networks.
  *   Microphotonics and nanophotonics: Development and application of novel nanoparticle fluorescent quantum-dots. Sensitive, multiplexed, high-throughput characterization of macromolecular properties of cells. Nanomaterials and nanodevices for biomedicine.
  *   Optogenetics: Novel research in employing light-activated channels and enzymes for manipulation of neural activity with temporal precision.  Utilizing nanophotonics, nanofibers, and genetic techniques for mapping and studying in real-time physiological processes in organs such as the brain and heart.
Proposals accepted anytime. Med-RA deadline to receive draft documents: Ten business days before submission to sponsor.

Nanoscale Interactions<https://www.nsf.gov/funding/pgm_summ.jsp?pims_id=505696>
The Nanoscale Interactions program is part of the Environmental Engineering and Sustainability cluster, which also includes: 1) the Environmental Engineering program; and 2) the Environmental Sustainability program.
The goal of the Nanoscale Interactions program is to support research to advance fundamental and quantitative understanding of the interactions of nanomaterials and nanosystems with biological and environmental media.
Materials of interest include one- to three-dimensional nanostructures, heterogeneous nano-bio hybrid assemblies, dendritic and micelle structures, quantum dots, and other nanoparticles. Such nanomaterials and systems frequently exhibit novel physical, chemical, photonic, electronic, and biological behavior as compared to the bulk scale.  Collaborative and interdisciplinary proposals are encouraged.
Research areas supported by the program include:

  *   Characterization of interactions at the interfaces of nanomaterials and nanosystems, including both simple nanoparticles and complex and/or heterogeneous composites and nanosystems, with surrounding biological and environmental media;
  *   Development of predictive tools based on the fundamental behavior of nanostructures to advance cost-effective and environmentally benign processing and engineering solutions over full-life material cycles;
  *   Examination of the transport, interaction, and impact of nanostructured materials and nanosystems on biological systems and the environment;
  *   Simulations of nanoparticle behavior at interfaces, in conjunction with experimental comparisons, and new theories and simulation approaches for determining the transport and transformation of nanoparticles in various media; and
  *   Investigations of quantum vibronic and spin phenomena with correlations to nano phenomena.
The Nanoscale Interactions program will support exploratory research projects on nanoscale interactions of quantum effects which explain macroscopic changes and physiological and metabolic processes; investigate quantum vibration and electron spin to elucidate nano phenomena and produce quantitative data and evidence of quantum effects.
Research in these areas will enable the design of nanostructured materials and heterogeneous nanosystems with desired chemical, electronic, photonic, biological, and mechanical properties for optimal and sustainable handling, manufacture, and utilization.
Proposals accepted anytime. Med-RA deadline to receive draft documents: Ten business days before submission to sponsor.

Fluid Dynamics<https://www.nsf.gov/funding/pgm_summ.jsp?pims_id=505698>
The Fluid Dynamics program is part of the Transport Phenomena cluster, which also includes 1) the Combustion and Fire Systems program; 2) the Particulate and Multiphase Processes program; and 3) the Thermal Transport Processes program.
The Fluid Dynamics program supports fundamental research toward gaining an understanding of the physics of various fluid dynamics phenomena. Proposed research should contribute to basic scientific understanding via experiments, theoretical developments, and computational discovery.
Major areas of interest and activity in the program include:

  *   Turbulence and transition: High Reynolds number experiments; large eddy simulation; direct numerical simulation; transition to turbulence; 3-D boundary layers; separated flows; multi-phase turbulent flows; flow control and drag reduction. A new area of emphasis is high speed boundary layer transition and turbulence; the focus would be for flows at Mach numbers greater than 5 to understand cross-mode interactions leading to boundary layer transition and the ensuing developing and fully developed turbulent boundary layer flows. Combined experiments and simulations are encouraged.
  *   Bio-fluid physics: Bio-inspired flows; biological flows with emphasis on flow physics.
  *   Non-Newtonian fluid mechanics: Viscoelastic flows; solutions of macro-molecules.
  *   Microfluidics and nanofluidics: Micro-and nano-scale flow physics.
  *   Wind and ocean energy harvesting: Focused on fundamental fluid dynamics associated with renewal energy.
  *   Fluid-structure interactions: NSF interests are in general FSI applications across the low- to high-Reynolds number range. In addition an NSF-AFOSR (Air Force Office of Scientific Research) joint funding area is the theory, modeling and/or experiments for hypersonic applications. Proposals will be jointly reviewed by NSF and AFOSR using the NSF merit review process. Actual funding format and agency split for an award (depending on availability of funds) will be determined after the proposal selection process. The AFOSR program that participates in this initiative is the Aerothermodynamics program (program officer: Dr. Sarah Popkin<mailto:sarah.popkin at us.af.mil>).
  *   Canonical configurations: Experimental research is encouraged to develop spatiotemporally resolved databases for canonical configurations to either confirm historical results or to provide data in an unexplored parameter region. Fidelity and completeness for theoretical/computational validation are key attributes of the proposed experimental data.
  *   Artificial intelligence (AI)/machine learning: Innovative AI ideas related to the use of machine learning and other AI approaches in fluid dynamics research to model and control the flows are encouraged. Verifying new models with canonical configurations, when appropriate, is encouraged for the Computational and Data-Enabled Science & Engineering (CDS&E) program.
  *   Instrumentation and Flow Diagnostics: Instrument development for time-space resolved measurements; shear stress sensors; novel flow imaging; and velocimetry.
Proposals accepted anytime. Med-RA deadline to receive draft documents: Ten business days before submission to sponsor.

To search for additional funding opportunities, please visit CoM’s unofficial funding opportunities blog<https://urldefense.proofpoint.com/v2/url?u=https-3A__fsucomgrants.wordpress.com_&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=-WQkPIXZLCgXlX-d14DY8B-SG-GvP9FZHr_Gv8sUuTQ&s=ErAzzubGxiJsWCKGnlFjfXV6980C-DCl-AxzFLHMVYQ&e=>.

-------------- next part --------------
An HTML attachment was scrubbed...
URL: <http://lists.fsu.edu/pipermail/com_funding_opportunities/attachments/20210719/54a3835c/attachment.html>